Loading…
Reported covered position: Asst for Policy, Speaker Dennis HastertAdmin Asst; Leg Dir; Leg Asst, Cong. Porter GossHouse Rules Comm Assoc, Subcomm Staff Dir.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Lung Cancer Screening and Prevention Act of 2025
Client: DELFI DIAGNOSTICS · Firm: W STRATEGIES, LLC
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
Lung Cancer Screening and Prevention Act of 2025
Client: DELFI DIAGNOSTICS · Firm: W STRATEGIES, LLC
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ABBVIE INC. via W STRATEGIES, LLC
2026 · third_quarter · Q3
Education around data privacy. Education about the drug approval process at FDA.
Filing targets: HOUSE OF REPRESENTATIVES
DELFI DIAGNOSTICS via W STRATEGIES, LLC
2026 · third_quarter · Q3
Source: Senate LDA
| ABBVIE, INC. |
| 57 |
| 2013–2026 |
| ASTRAZENECA PHARMACEUTICALS LP | 52 | 2014–2026 |
| 23ANDME, INC. | 50 | 2011–2023 |
| ALEXION PHARMACEUTICALS | 50 | 2010–2021 |
| ENOVIS | 50 | 2010–2022 |
| JUUL LABS, INC | 39 | 2017–2026 |
| IPSEN BIOPHARMACEUTICALS, INC. | 38 | 2017–2026 |
| SANOFI U.S. SERVICES, INC. | 38 | 2017–2026 |
| CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 36 | 2011–2019 |
| MERCK & CO., INC. | 36 | 2018–2026 |
| BIOGEN | 35 | 2010–2018 |
| SUPERNUS PHARMACEUTICALS FKA SAGE THERAPEUTICS | 33 | 2018–2025 |
| GILEAD SCIENCES, INC. | 32 | 2019–2026 |
| INCYTE CORPORATION | 30 | 2019–2026 |
| UNITEDHEALTH GROUP, INC. | 26 | 2011–2016 |
| DELFI DIAGNOSTICS | 20 | 2022–2026 |
| MCKESSON CORPORATION | 20 | 2016–2025 |
| GENZYME CORPORATION | 19 | 2010–2014 |
| GLOBAL BLOOD THERAPEUTICS | 17 | 2019–2022 |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | 17 | 2022–2026 |
| ACTELION PHARMACEUTICALS US INC | 15 | 2015–2018 |
| HORIZON PHARMA USA, INC. | 15 | 2013–2017 |
| MEDIMMUNE, LLC. | 14 | 2011–2013 |
| PHLOW CORP. | 14 | 2023–2026 |
| VIR BIOTECHNOLOGY, INC. | 14 | 2020–2023 |
| KARUNA THERAPEUTICS | 11 | 2022–2024 |
| ALVEO TECHNOLOGIES | 10 | 2024–2026 |
| IOVANCE BIOTHERAPEUTICS, INC. | 10 | 2020–2022 |
| SECURE IDENTITY, LLC | 10 | 2020–2022 |
| MODERNA, INC. | 9 | 2019–2021 |
| THERMO FISHER SCIENTIFIC INC. | 8 | 2021–2022 |
| RAPTOR PHARMACEUTICAL CORP. | 7 | 2015–2016 |
| UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA) | 7 | 2025–2026 |
| ELEVATEBIO | 6 | 2025 |
| PAPERBIRCH STRATEGIES ON BEHALF OF AP3 BIOMEDICAL | 6 | 2025–2026 |
| GENENTECH INC | 5 | 2010–2011 |
| STOKE THERAPEUTICS | 5 | 2022 |
| BRISTOL-MYERS SQUIBB COMPANY | 4 | 2026 |
| DUTKO WORLDWIDE, LLC ON BEHALF OF EISAI, INC. | 4 | 2010–2011 |
| TESARO, INC. | 4 | 2019 |
| DUTKO WORLDWIDE, LLC ON BEHALF OF COALITION TO ADVANCE HEALTHCARE REFORM | 3 | 2010 |
| DUTKO WORLDWIDE, LLC ON BEHALF OF UNITED HEALTH CARE | 3 | 2010 |
| DYNE THERAPEUTICS, INC. | 3 | 2026 |
| EXELIXIS, INC. | 3 | 2026 |
| KAILERA THERAPEUTICS INC. | 2 | 2026 |
Lung Cancer Screening and Prevention Act of 2025
Client: DELFI DIAGNOSTICS · Firm: W STRATEGIES, LLC
Education around innovative testing for early detection of lung cancer. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Client: ABBOTT LABORATORIES · Firm: W STRATEGIES, LLC
Issues related to infant formula access. Issues related to DMEPOS reimbursement by CMS. H.R.2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Client: ABBOTT LABORATORIES · Firm: W STRATEGIES, LLC
Issues related to infant formula access. H.R.2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Client: ABBOTT LABORATORIES · Firm: W STRATEGIES, LLC
Issues related to infant formula access. Issues related to DMEPOS reimbursement by CMS. H.R.2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Impacts and Outcomes for Health Career Training Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: W STRATEGIES, LLC
Public Law 119-21: One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. PBM reform legislation. Issues around drug pricing.
Impacts and Outcomes for Health Career Training Act
Client: GLAXOSMITHKLINE · Firm: W STRATEGIES, LLC
Implementation of H.R.5376 - Inflation Reduction Act of 2022. Issues around access to vaccines Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Impacts and Outcomes for Health Career Training Act
Client: GILEAD SCIENCES, INC. · Firm: W STRATEGIES, LLC
Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Impacts and Outcomes for Health Career Training Act
Client: GILEAD SCIENCES, INC. · Firm: W STRATEGIES, LLC
Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Impacts and Outcomes for Health Career Training Act
Client: GLAXOSMITHKLINE · Firm: W STRATEGIES, LLC
Implementation of H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act Issues around drug pricing.
Impacts and Outcomes for Health Career Training Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: W STRATEGIES, LLC
Public Law 119-21: One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. PBM reform legislation. 340(b) reform. FY 2027 National Defense Authorization Act. Issues around drug pricing including CMMI drug demonstration projects.
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Implementation of the Inflation Reduction Act. Education around NIH funding Issues around drug pricing.
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Implementation of the Inflation Reduction Act. Education around NIH funding Issues around drug pricing.
Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. Issues related to drug pricing including potential legislation to impose Most Favored Nation pricing in Medicare. CMS Guard demonstration project".
Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. Issues related to drug pricing.
Issues around drug pricing. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act.
Issues around drug pricing. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Education about 340b program.
Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. Issues related to drug pricing.
Issues around drug pricing. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Education about 340b program.
Implementation of H.R.5376 - Inflation Reduction Act of 2022. Issues around drug pricing. Education about FDA regulatory process.
Implementation H.R.5376 - Inflation Reduction Act of 2022. Issues around drug pricing.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CALIFORNIA LIFE SCIENCES · Firm: W STRATEGIES, LLC
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). H.R.1 - One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Implementation of the Inflation Reduction Act. H.R.1492 - EPIC Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: IPSEN BIOPHARMACEUTICALS, INC. · Firm: W STRATEGIES, LLC
Monitored H.R.1 - One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: W STRATEGIES, LLC
H.R.1 - One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA) · Firm: W STRATEGIES, LLC
Monitored H.R.1 - One Big Beautiful Bill Act. Monitored health care legislation and regulation, including telehealth and Medicare Advantage.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: INCYTE CORPORATION · Firm: W STRATEGIES, LLC
Issues related to Medicaid Drug Rebate program rule. H.R.1 - One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: SANOFI U.S. SERVICES, INC. · Firm: W STRATEGIES, LLC
H.R.1 - One Big Beautiful Bill Act." Implementation of Inflation Reduction Act. H.R.1492 - EPIC Act of 2025.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: MERCK & CO., INC. · Firm: W STRATEGIES, LLC
H.R.1 - One Big Beautiful Bill Act. H.R.1492: EPIC Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: W STRATEGIES, LLC
H.R.1 - One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. H.R.1492 - EPIC Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ABBVIE INC. · Firm: W STRATEGIES, LLC
Medicare Implementation of the Inflation Reduction Act. H.R.1 - One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: W STRATEGIES, LLC
H.R.1 - One Big Beautiful Bill Act. Education about innovative therapies treating Alzheimer's dementia and access to innovative therapies in Medicare.
Lung Cancer Screening and Prevention Act of 2025
Client: DELFI DIAGNOSTICS · Firm: W STRATEGIES, LLC
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
Lung Cancer Screening and Prevention Act of 2025
Client: DELFI DIAGNOSTICS · Firm: W STRATEGIES, LLC
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
Lung Cancer Screening and Prevention Act of 2025
Client: DELFI DIAGNOSTICS · Firm: W STRATEGIES, LLC
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
Lung Cancer Screening and Prevention Act of 2025
Client: DELFI DIAGNOSTICS · Firm: W STRATEGIES, LLC
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: SANOFI U.S. SERVICES, INC. · Firm: W STRATEGIES, LLC
H.R.1 - One Big Beautiful Bill Act." Implementation of Inflation Reduction Act. H.R.1492 - EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: CALIFORNIA LIFE SCIENCES · Firm: W STRATEGIES, LLC
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). H.R.1 - One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Implementation of the Inflation Reduction Act. H.R.1492 - EPIC Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: MERCK & CO., INC. · Firm: W STRATEGIES, LLC
H.R.1 - One Big Beautiful Bill Act. H.R.1492: EPIC Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: SANOFI U.S. SERVICES, INC. · Firm: W STRATEGIES, LLC
Implementation of Inflation Reduction Act. H.R.1492 - EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: MERCK & CO., INC. · Firm: W STRATEGIES, LLC
Public Law 119-21: One Big Beautiful Bill Act. H.R.1492: EPIC Act. Education around access to vaccines.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: W STRATEGIES, LLC
Implementation of H.R.5376 Inflation Reduction Act. H.R.1492 - EPIC Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: CALIFORNIA LIFE SCIENCES · Firm: W STRATEGIES, LLC
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). H.R.946 - ORPHAN Cures Act. Implementation of the Inflation Reduction Act. H.R.1492 - EPIC Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: W STRATEGIES, LLC
H.R.1 - One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. H.R.1492 - EPIC Act.
To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Client: ABBOTT LABORATORIES · Firm: W STRATEGIES, LLC
Issues related to infant formula access. H.R.2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Client: ABBOTT LABORATORIES · Firm: W STRATEGIES, LLC
Issues related to infant formula access. H.R.2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Client: ABBOTT LABORATORIES · Firm: W STRATEGIES, LLC
Issues related to infant formula access. H.R.2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Impacts and Outcomes for Health Career Training Act
Client: GILEAD SCIENCES, INC. · Firm: W STRATEGIES, LLC
Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act.
Impacts and Outcomes for Health Career Training Act
Client: GLAXOSMITHKLINE · Firm: W STRATEGIES, LLC
Implementation of H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act Issues around drug pricing.
Impacts and Outcomes for Health Career Training Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: W STRATEGIES, LLC
Public Law 119-21: One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. PBM reform legislation.
Impacts and Outcomes for Health Career Training Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: W STRATEGIES, LLC
Implementation of H.R.5376 Inflation Reduction Act. H.R.1492 - EPIC Act.
Impacts and Outcomes for Health Career Training Act
Client: GILEAD SCIENCES, INC. · Firm: W STRATEGIES, LLC
Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act.
Impacts and Outcomes for Health Career Training Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: W STRATEGIES, LLC
H.R.1 - One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. H.R.1492 - EPIC Act.
Impacts and Outcomes for Health Career Training Act
Client: GLAXOSMITHKLINE · Firm: W STRATEGIES, LLC
Implementation of H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act.
Impacts and Outcomes for Health Career Training Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: W STRATEGIES, LLC
Public Law 119-21: One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. PBM reform legislation. Issues around drug pricing.
Issues around drug pricing. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act.
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Implementation of the Inflation Reduction Act. Education around NIH funding.
Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act.
Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act.
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Implementation of the Inflation Reduction Act. Education around NIH funding Issues around drug pricing.
H.R.1 - One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act.
Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act.
Issues related to Medicaid Drug Rebate program rule. H.R.1 - One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act.
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). H.R.946 - ORPHAN Cures Act. Implementation of the Inflation Reduction Act. H.R.1492 - EPIC Act.
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). H.R.1 - One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Implementation of the Inflation Reduction Act. H.R.1492 - EPIC Act.
To provide for a limitation on availability of funds for Department of Health and Human Services, National Institutes of Health National Institute on Drug Abuse for fiscal year 2024.
Client: CALIFORNIA LIFE SCIENCES · Firm: W STRATEGIES, LLC
H.R.1990- American Innovation and R&D Competitiveness Act of 2023.
To provide for a limitation on availability of funds for Department of Health and Human Services, National Institutes of Health National Institute on Drug Abuse for fiscal year 2024.
Client: CALIFORNIA LIFE SCIENCES · Firm: W STRATEGIES, LLC
H.R.1990- American Innovation and R&D Competitiveness Act of 2023.
Implementation of H.R.5376 - Inflation Reduction Act of 2022. H.R.1 - One Big Beautiful Bill Act.
H.R.1492 - EPIC Act. Implementation H.R.5376 - Inflation Reduction Act of 2022. H.R.1 - One Big Beautiful Bill Act.
Methane Waste Prevention Act of 2021
Client: GILEAD SCIENCES, INC. · Firm: W STRATEGIES, LLC
H.R.1492 - EPIC Act. Implementation H.R.5376 - Inflation Reduction Act of 2022.
Implementation of H.R.5376 - Inflation Reduction Act of 2022. H.R.1492: EPIC Act.
Methane Waste Prevention Act of 2021
Client: GILEAD SCIENCES, INC. · Firm: W STRATEGIES, LLC
H.R.1492 - EPIC Act. Implementation H.R.5376 - Inflation Reduction Act of 2022. H.R.1 - One Big Beautiful Bill Act.
Inflation Reduction Act of 2022
Client: IPSEN BIOPHARMACEUTICALS, INC. · Firm: W STRATEGIES, LLC
Issues pertaining to H.R.5376 - Inflation Reduction Act of 2022
Implementation of H.R.5376 - Inflation Reduction Act of 2022. H.R.1492: EPIC Act.
H.R.1492 - EPIC Act. Implementation H.R.5376 - Inflation Reduction Act of 2022.
Issues related to Medicaid Drug Rebate program rule. H.R.5376 - Implementation of Inflation Reduction Act.
Implementation of H.R.5376 - Inflation Reduction Act of 2022.
H.R.1492 - EPIC Act. Implementation H.R.5376 - Inflation Reduction Act of 2022. H.R.1 - One Big Beautiful Bill Act.
Implementation of H.R.5376 - Inflation Reduction Act of 2022. H.R.1 - One Big Beautiful Bill Act.
Inflation Reduction Act of 2022
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: W STRATEGIES, LLC
Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs. H.R.946 - ORPHAN Cures Act.
Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs. H.R.946 - ORPHAN Cures Act.
American Relief Act, 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: W STRATEGIES, LLC
Implementation of H.R.5376 Inflation Reduction Act. H.R.7174 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform.
H.R.830 - HELP Copays Act. Legislation to reform PBMs. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform.
Legislation around Vaccine Injury Compensation Modernization. Reauthorization of Pandemic All Hazards Preparedness (PAHPA) Act. H.R.2923 - Living Donor Protection Act of 2023. H.R.5378 - Lower Costs, More Transparency Act. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform.
H.R.5378 - Lower Costs, More Transparency Act. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform.
H.R.5378 - Lower Costs, More Transparency Act. Education about the 340(b) program. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: CALIFORNIA LIFE SCIENCES · Firm: W STRATEGIES, LLC
CMS rule on Medicare Coverage for Innovative Technology and H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Implementation of Inflation Reduction Act of 2022.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: MEDTRONIC, INC. · Firm: W STRATEGIES, LLC
H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to AI in health care.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: MEDTRONIC, INC. · Firm: W STRATEGIES, LLC
H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to AI in health care.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: MEDTRONIC, INC. · Firm: W STRATEGIES, LLC
H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Medicare coverage for breakthrough medical devices. Issues related to AI in health care.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: MEDTRONIC, INC. · Firm: W STRATEGIES, LLC
H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to AI in health care.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: CALIFORNIA LIFE SCIENCES · Firm: W STRATEGIES, LLC
CMS rule on Medicare Coverage for Innovative Technology and H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: CALIFORNIA LIFE SCIENCES · Firm: W STRATEGIES, LLC
CMS rule on Medicare Coverage for Innovative Technology and H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: CALIFORNIA LIFE SCIENCES · Firm: W STRATEGIES, LLC
CMS rule on Medicare Coverage for Innovative Technology and H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Implementation of Inflation Reduction Act of 2022.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION · Firm: W STRATEGIES, LLC
H.R.1770 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: MCKESSON CORPORATION · Firm: W STRATEGIES, LLC
H.R.1770 - Equitable Community Access to Pharmacist Services Act.
H.R.2630 - Safe Step Act.
American Innovation and R&D Competitiveness Act of 2023
Client: CALIFORNIA LIFE SCIENCES · Firm: W STRATEGIES, LLC
H.R.2673 - American Innovation and R&D Competitiveness Act of 2023.
American Innovation and R&D Competitiveness Act of 2023
Client: CALIFORNIA LIFE SCIENCES · Firm: W STRATEGIES, LLC
H.R.2673 - American Innovation and R&D Competitiveness Act of 2023.
American Innovation and R&D Competitiveness Act of 2023
Client: CALIFORNIA LIFE SCIENCES · Firm: W STRATEGIES, LLC
H.R.2673 - American Innovation and R&D Competitiveness Act of 2023.
Education around innovative testing for early detection of lung cancer. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES
INCYTE CORPORATION via W STRATEGIES, LLC
2026 · third_quarter · Q3
Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. Issues related to drug pricing including potential legislation to impose Most Favored Nation pricing in Medicare. CMS Guard demonstration project".
Filing targets: HOUSE OF REPRESENTATIVES
MEDTRONIC, INC. via W STRATEGIES, LLC
2026 · third_quarter · Q3
CMS coverage of renal denervation devices. Issues related to AI in health care. FY 2027 NDAA as it relates to right to repair legislation.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via W STRATEGIES, LLC
2026 · third_quarter · Q3
PBM reform legislation. 340(b) reform. FY 2027 National Defense Authorization Act. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
SANOFI U.S. SERVICES, INC. via W STRATEGIES, LLC
2026 · third_quarter · Q3
Issues around drug pricing. Education on vaccines.
Filing targets: HOUSE OF REPRESENTATIVES
UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA) via W STRATEGIES, LLC
2026 · third_quarter · Q3
Monitored Public Law 119-21: One Big Beautiful Bill Act. Monitored health care legislation and regulation, including telehealth and Medicare Advantage.
PHLOW CORP. via W STRATEGIES, LLC
2026 · third_quarter · Q3
Education about efforts to provide greater resiliency in the drug supply chain. FY 2027 National Defense Authorization Act (NDAA).
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)
PAPERBIRCH STRATEGIES ON BEHALF OF AP3 BIOMEDICAL via W STRATEGIES, LLC
2026 · third_quarter · Q3
Education around innovation in prostate cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES
OTSUKA AMERICA PHARMACEUTICAL, INC. via W STRATEGIES, LLC
2026 · third_quarter · Q3
Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
MERCK & CO., INC. via W STRATEGIES, LLC
2026 · third_quarter · Q3
Education around access to vaccines. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
KAILERA THERAPEUTICS INC. via W STRATEGIES, LLC
2026 · third_quarter · Q3
Access to innovative drug therapies.
JUUL LABS INC via W STRATEGIES, LLC
2026 · third_quarter · Q3
Issues related to enforcement of illicit tobacco products, including importation of counterfeit products, and unregulated nicotine products. Education related to implementation of Public Law 111-31, the Family Smoking Prevention and Tobacco Control Act, and PMTA submissions for deemed tobacco products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IPSEN BIOPHARMACEUTICALS, INC. via W STRATEGIES, LLC
2026 · third_quarter · Q3
Monitored Public Law 119-21: One Big Beautiful Bill Act. Issues related to drug pricing.
GLAXOSMITHKLINE via W STRATEGIES, LLC
2026 · third_quarter · Q3
Implementation of H.R.5376 - Inflation Reduction Act of 2022. Issues around drug pricing. Education about FDA regulatory process.
Filing targets: HOUSE OF REPRESENTATIVES
GILEAD SCIENCES, INC. via W STRATEGIES, LLC
2026 · third_quarter · Q3
Implementation H.R.5376 - Inflation Reduction Act of 2022. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
EXELIXIS, INC. via W STRATEGIES, LLC
2026 · third_quarter · Q3
Reforms to the Inflation Reduction Act as it relates to drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
DYNE THERAPEUTICS, INC. via W STRATEGIES, LLC
2026 · third_quarter · Q3
Education about access to rare disease therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA LIFE SCIENCES via W STRATEGIES, LLC
2026 · third_quarter · Q3
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). Education around NIH funding. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
BRISTOL-MYERS SQUIBB COMPANY via W STRATEGIES, LLC
2026 · third_quarter · Q3
Issues around drug pricing. Regulation of Fixed dose drug combinations.
Filing targets: HOUSE OF REPRESENTATIVES
ASTRAZENECA PHARMACEUTICALS LP via W STRATEGIES, LLC
2026 · third_quarter · Q3
Issues around drug pricing. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES
ALVEO TECHNOLOGIES via W STRATEGIES, LLC
2026 · third_quarter · Q3
Education related to diagnostic testing, especially as it relates to bird flu.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBOTT LABORATORIES via W STRATEGIES, LLC
2026 · third_quarter · Q3
Issues related to infant formula access. Issues related to DMEPOS reimbursement by CMS. H.R.2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES
KAILERA THERAPEUTICS INC. via W STRATEGIES, LLC
2026 · third_quarter · RR
Access to innovative drug therapies.
UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA) via W STRATEGIES, LLC
2026 · second_quarter · Q2
Monitored Public Law 119-21: One Big Beautiful Bill Act. Monitored health care legislation and regulation, including telehealth and Medicare Advantage.
SANOFI U.S. SERVICES, INC. via W STRATEGIES, LLC
2026 · second_quarter · Q2
Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing. Education on vaccines.
Filing targets: HOUSE OF REPRESENTATIVES
PHLOW CORP. via W STRATEGIES, LLC
2026 · second_quarter · Q2
Education about efforts to provide greater resiliency in the drug supply chain. FY 2027 National Defense Authorization Act (NDAA).
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via W STRATEGIES, LLC
2026 · second_quarter · Q2
Public Law 119-21: One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. PBM reform legislation. 340(b) reform. FY 2027 National Defense Authorization Act. Issues around drug pricing including CMMI drug demonstration projects.
Filing targets: HOUSE OF REPRESENTATIVES
PAPERBIRCH STRATEGIES ON BEHALF OF AP3 BIOMEDICAL via W STRATEGIES, LLC
2026 · second_quarter · Q2
Education around innovation in prostate cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via W STRATEGIES, LLC
2026 · second_quarter · Q2
Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
MERCK & CO., INC. via W STRATEGIES, LLC
2026 · second_quarter · Q2
Education around access to vaccines. Issues related to drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
MEDTRONIC, INC. via W STRATEGIES, LLC
2026 · second_quarter · Q2
CMS coverage of renal denervation devices. Issues related to AI in health care. FY 2027 NDAA as it relates to right to repair legislation.
Filing targets: HOUSE OF REPRESENTATIVES
JUUL LABS INC via W STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to enforcement of illicit tobacco products, including importation of counterfeit products, and unregulated nicotine products. Education related to implementation of Public Law 111-31, the Family Smoking Prevention and Tobacco Control Act, and PMTA submissions for deemed tobacco products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IPSEN BIOPHARMACEUTICALS, INC. via W STRATEGIES, LLC
2026 · second_quarter · Q2
Monitored Public Law 119-21: One Big Beautiful Bill Act. Issues related to drug pricing.
INCYTE CORPORATION via W STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. Issues related to drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
GLAXOSMITHKLINE via W STRATEGIES, LLC
2026 · second_quarter · Q2
Implementation of H.R.5376 - Inflation Reduction Act of 2022. Issues around access to vaccines Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
GILEAD SCIENCES, INC. via W STRATEGIES, LLC
2026 · second_quarter · Q2
Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
EXELIXIS, INC. via W STRATEGIES, LLC
2026 · second_quarter · Q2
Reforms to the Inflation Reduction Act as it relates to drug pricing.
DYNE THERAPEUTICS, INC. via W STRATEGIES, LLC
2026 · second_quarter · Q2
Education about access to rare disease therapies.
Filing targets: HOUSE OF REPRESENTATIVES
DELFI DIAGNOSTICS via W STRATEGIES, LLC
2026 · second_quarter · Q2
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES
CALIFORNIA LIFE SCIENCES via W STRATEGIES, LLC
2026 · second_quarter · Q2
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Implementation of the Inflation Reduction Act. Education around NIH funding Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
BRISTOL-MYERS SQUIBB COMPANY via W STRATEGIES, LLC
2026 · second_quarter · Q2
Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
ASTRAZENECA PHARMACEUTICALS LP via W STRATEGIES, LLC
2026 · second_quarter · Q2
Issues around drug pricing. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Education about 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALVEO TECHNOLOGIES via W STRATEGIES, LLC
2026 · second_quarter · Q2
Education related to diagnostic testing, especially as it relates to bird flu.
Filing targets: HOUSE OF REPRESENTATIVES
ABBVIE INC. via W STRATEGIES, LLC
2026 · second_quarter · Q2
Education and legislation related to reform of the 340(b) program. Education around data privacy.
Medicare Implementation of the Inflation Reduction Act. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
ABBOTT LABORATORIES via W STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to infant formula access. Issues related to DMEPOS reimbursement by CMS. H.R.2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES
EXELIXIS, INC. via W STRATEGIES, LLC
2026 · second_quarter · RR
Education about access to prescription drugs.
SANOFI U.S. SERVICES, INC. via W STRATEGIES, LLC
2026 · first_quarter · Q1
Public Law 119-21: One Big Beautiful Bill Act. Implementation of Inflation Reduction Act. Issues around drug pricing. Education on vaccines.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via W STRATEGIES, LLC
2026 · first_quarter · Q1
Public Law 119-21: One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. PBM reform legislation. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
OTSUKA AMERICA PHARMACEUTICAL, INC. via W STRATEGIES, LLC
2026 · first_quarter · Q1
Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
GLAXOSMITHKLINE via W STRATEGIES, LLC
2026 · first_quarter · Q1
Implementation of H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
GILEAD SCIENCES, INC. via W STRATEGIES, LLC
2026 · first_quarter · Q1
Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
ASTRAZENECA PHARMACEUTICALS LP via W STRATEGIES, LLC
2026 · first_quarter · Q1
Issues around drug pricing. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Education about 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDTRONIC, INC. via W STRATEGIES, LLC
2026 · first_quarter · Q1
CMS coverage of renal denervation devices. Issues related to AI in health care. FY 2026 NDAA as it relates to right to repair legislation.
Filing targets: HOUSE OF REPRESENTATIVES
BRISTOL-MYERS SQUIBB COMPANY via W STRATEGIES, LLC
2026 · first_quarter · Q1
Education about the value of biopharmaceutical innovation and related issues.
ABBVIE INC. via W STRATEGIES, LLC
2026 · first_quarter · Q1
Medicare Implementation of the Inflation Reduction Act. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Education and legislation related to reform of the 340(b) program. Education around data privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBOTT LABORATORIES via W STRATEGIES, LLC
2026 · first_quarter · Q1
Issues related to infant formula access. H.R.2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA) via W STRATEGIES, LLC
2026 · first_quarter · Q1
Monitored Public Law 119-21: One Big Beautiful Bill Act. Monitored health care legislation and regulation, including telehealth and Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
PHLOW CORP. via W STRATEGIES, LLC
2026 · first_quarter · Q1
Education about efforts to provide greater resiliency in the drug supply chain.
Filing targets: HOUSE OF REPRESENTATIVES
PAPERBIRCH STRATEGIES ON BEHALF OF AP3 BIOMEDICAL via W STRATEGIES, LLC
2026 · first_quarter · Q1
Education around innovation in prostate cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES
MERCK & CO., INC. via W STRATEGIES, LLC
2026 · first_quarter · Q1
Education around access to vaccines. Public Law 119-21: One Big Beautiful Bill Act.
Filing targets: HOUSE OF REPRESENTATIVES
JUUL LABS INC via W STRATEGIES, LLC
2026 · first_quarter · Q1
Issues related to enforcement of illicit tobacco products, including importation of counterfeit products, and unregulated nicotine products. Education related to implementation of Public Law 111-31, the Family Smoking Prevention and Tobacco Control Act, and PMTA submissions for deemed tobacco products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IPSEN BIOPHARMACEUTICALS, INC. via W STRATEGIES, LLC
2026 · first_quarter · Q1
Monitored Public Law 119-21: One Big Beautiful Bill Act. Issues related to drug pricing.
INCYTE CORPORATION via W STRATEGIES, LLC
2026 · first_quarter · Q1
Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. Issues related to drug pricing.
Education around access to innovative therapies in dermatology.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS)
DELFI DIAGNOSTICS via W STRATEGIES, LLC
2026 · first_quarter · Q1
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES
CALIFORNIA LIFE SCIENCES via W STRATEGIES, LLC
2026 · first_quarter · Q1
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Implementation of the Inflation Reduction Act. Education around NIH funding Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
ALVEO TECHNOLOGIES via W STRATEGIES, LLC
2026 · first_quarter · Q1
Education related to diagnostic testing, especially as it relates to bird flu.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DYNE THERAPEUTICS, INC. via W STRATEGIES, LLC
2026 · second_quarter · RR
Education about access to rare disease therapies.
BRISTOL-MYERS SQUIBB COMPANY via W STRATEGIES, LLC
2026 · first_quarter · RR
Education about the value of biopharmaceutical innovation and related issues.
ELEVATEBIO via W STRATEGIES, LLC
2025 · fourth_quarter · 4T
Education about innovation in cell and gene therapies.
MERCK & CO., INC. via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Education around access to vaccines. Public Law 119-21: One Big Beautiful Bill Act.
Filing targets: HOUSE OF REPRESENTATIVES
MEDTRONIC, INC. via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
CMS coverage of renal denervation devices. Proposed CMS WISER demonstration. Issues related to AI in health care. FY 2026 NDAA as it relates to right to repair legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act.
Education about access to HIV medicines. Education about the 340(b) program.
Filing targets: HOUSE OF REPRESENTATIVES
DELFI DIAGNOSTICS via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
INCYTE CORPORATION via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Education around access to innovative therapies in dermatology. Issues related to the 340(b)program.
Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES
ELEVATEBIO via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Education about innovation in cell and gene therapies.
ALVEO TECHNOLOGIES via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Education related to diagnostic testing, especially as it relates to bird flu.
Filing targets: HOUSE OF REPRESENTATIVES
PHLOW CORP. via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Education about efforts to provide greater resiliency in the drug supply chain.
Filing targets: HOUSE OF REPRESENTATIVES
PAPERBIRCH STRATEGIES ON BEHALF OF AP3 BIOMEDICAL via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Education around innovation in prostate cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES
JUUL LABS INC via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Issues related to enforcement of illicit tobacco products, including importation of counterfeit products, and unregulated nicotine products. Education related to implementation of Public Law 111-31, the Family Smoking Prevention and Tobacco Control Act, and PMTA submissions for deemed tobacco products.
Filing targets: HOUSE OF REPRESENTATIVES
IPSEN BIOPHARMACEUTICALS, INC. via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Monitored Public Law 119-21: One Big Beautiful Bill Act.
UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA) via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Monitored Public Law 119-21: One Big Beautiful Bill Act. Monitored health care legislation and regulation, including telehealth and Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
SUPERNUS PHARMACEUTICALS FKA SAGE THERAPEUTICS via W STRATEGIES, LLC
2025 · fourth_quarter · 4T
Education and awareness of mental health issues especially as it relates to access for postpartum depression treatment and major depressive disorder.
CALIFORNIA LIFE SCIENCES via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act). Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Implementation of the Inflation Reduction Act. Education around NIH funding Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
ASTRAZENECA PHARMACEUTICALS LP via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Issues around drug pricing. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE INC. via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Education and legislation related to reform of the 340(b) program. Education around data privacy.
Medicare Implementation of the Inflation Reduction Act. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBOTT LABORATORIES via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Issues related to infant formula access. H.R.2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI U.S. SERVICES, INC. via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Public Law 119-21: One Big Beautiful Bill Act. Implementation of Inflation Reduction Act. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Public Law 119-21: One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. PBM reform legislation. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
OTSUKA AMERICA PHARMACEUTICAL, INC. via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
GLAXOSMITHKLINE via W STRATEGIES, LLC
2025 · fourth_quarter · Q4
Implementation of H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act Issues around drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES
UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA) via W STRATEGIES, LLC
2025 · third_quarter · Q3
Monitored Public Law 119-21: One Big Beautiful Bill Act. Monitored health care legislation and regulation, including telehealth and Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
SANOFI U.S. SERVICES, INC. via W STRATEGIES, LLC
2025 · third_quarter · Q3
Public Law 119-21: One Big Beautiful Bill Act. Implementation of Inflation Reduction Act.
Filing targets: HOUSE OF REPRESENTATIVES
SUPERNUS PHARMACEUTICALS FKA SAGE THERAPEUTICS via W STRATEGIES, LLC
2025 · third_quarter · Q3
Education and awareness of mental health issues especially as it relates to access for postpartum depression treatment and major depressive disorder.
PHLOW CORP. via W STRATEGIES, LLC
2025 · third_quarter · Q3
Education about efforts to provide greater resiliency in the drug supply chain.
Filing targets: HOUSE OF REPRESENTATIVES
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via W STRATEGIES, LLC
2025 · third_quarter · Q3
Public Law 119-21: One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. PBM reform legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PAPERBIRCH STRATEGIES ON BEHALF OF AP3 BIOMEDICAL via W STRATEGIES, LLC
2025 · third_quarter · Q3
Education around innovation in prostate cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES
OTSUKA AMERICA PHARMACEUTICAL, INC. via W STRATEGIES, LLC
2025 · third_quarter · Q3
Public Law 119-21: One Big Beautiful Bill Act.
Filing targets: HOUSE OF REPRESENTATIVES
MERCK & CO., INC. via W STRATEGIES, LLC
2025 · third_quarter · Q3
Public Law 119-21: One Big Beautiful Bill Act. H.R.1492: EPIC Act. Education around access to vaccines.
Filing targets: HOUSE OF REPRESENTATIVES
MEDTRONIC, INC. via W STRATEGIES, LLC
2025 · third_quarter · Q3
Ensuring Patient Access to Critical Breakthrough Products Act of 2025. CMS coverage of renal derivation devices. Proposed CMS WISER demonstration. Issues related to AI in health care. FY 2026 NDAA as it relates to right to repair legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE